vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $207.8M, roughly 1.6× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 2.4%, a 55.0% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-7.4M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
IDYA vs KFRC — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $330.4M |
| Net Profit | $119.2M | $7.9M |
| Gross Margin | — | 27.3% |
| Operating Margin | 52.2% | 3.6% |
| Net Margin | 57.4% | 2.4% |
| Revenue YoY | — | 0.1% |
| Net Profit YoY | 330.1% | -2.7% |
| EPS (diluted) | $1.33 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | — | $332.0M | ||
| Q3 25 | $207.8M | $332.6M | ||
| Q2 25 | — | $334.3M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | $0 | $353.3M | ||
| Q2 24 | $0 | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | — | $5.2M | ||
| Q3 25 | $119.2M | $11.1M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $11.1M | ||
| Q3 24 | $-51.8M | $14.2M | ||
| Q2 24 | $-52.8M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | — | 27.1% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | — | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | 52.2% | 4.5% | ||
| Q2 25 | — | 4.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | — | 1.6% | ||
| Q3 25 | 57.4% | 3.3% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | — | $0.29 | ||
| Q3 25 | $1.33 | $0.63 | ||
| Q2 25 | — | $0.59 | ||
| Q1 25 | — | $0.45 | ||
| Q4 24 | — | $0.60 | ||
| Q3 24 | $-0.60 | $0.75 | ||
| Q2 24 | $-0.68 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $117.4M |
| Total Assets | $1.2B | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | — | $2.1M | ||
| Q3 25 | $786.9M | $1.3M | ||
| Q2 25 | — | $2.5M | ||
| Q1 25 | — | $444.0K | ||
| Q4 24 | — | $349.0K | ||
| Q3 24 | $920.0M | $127.0K | ||
| Q2 24 | $701.7M | $110.0K |
| Q1 26 | — | $117.4M | ||
| Q4 25 | — | $124.6M | ||
| Q3 25 | $1.1B | $132.1M | ||
| Q2 25 | — | $134.4M | ||
| Q1 25 | — | $138.0M | ||
| Q4 24 | — | $154.6M | ||
| Q3 24 | $1.2B | $167.4M | ||
| Q2 24 | $931.7M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | — | $365.6M | ||
| Q3 25 | $1.2B | $374.2M | ||
| Q2 25 | — | $373.6M | ||
| Q1 25 | — | $368.2M | ||
| Q4 24 | — | $357.8M | ||
| Q3 24 | $1.2B | $369.9M | ||
| Q2 24 | $973.7M | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | — |
| Free Cash FlowOCF − Capex | $142.2M | $-7.4M |
| FCF MarginFCF / Revenue | 68.4% | -2.2% |
| Capex IntensityCapex / Revenue | 0.0% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $19.7M | ||
| Q3 25 | $142.2M | $23.3M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $249.0K | ||
| Q4 24 | — | $21.8M | ||
| Q3 24 | $-49.2M | $31.0M | ||
| Q2 24 | $-32.9M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | — | $16.7M | ||
| Q3 25 | $142.2M | $19.8M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $20.9M | ||
| Q3 24 | $-49.7M | $27.5M | ||
| Q2 24 | $-33.9M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | — | 5.0% | ||
| Q3 25 | 68.4% | 6.0% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | -1.2% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | — | 0.9% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | 1.19× | 2.11× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
